Serum total iron-binding capacity and iron status in patients with non-dialysis-dependent chronic kidney disease: A cross-sectional study in Vietnam.
Serum total iron-binding capacity and iron status in patients with non-dialysis-dependent chronic kidney disease: A cross-sectional study in Vietnam. Asia Pac J Clin Nutr. 2020;29(1):48-54 Authors: Thang LV, Kien NT, Hung NV, Kien TQ, Dung NH, Huong NTT, Toan ND, Toan PQ, Vinh HT, Nghia VX, Usui T Abstract BACKGROUND AND OBJECTIVES: We performed this study to evaluate serum iron and ferritin concentrations, serum total iron-binding capacity (TIBC), and proportion of overall iron deficiency among patients with non-dialysisdependent chronic kidney disease (ND-CKD). METHODS AND STUDY DESIGN: A hospital-based cross-sectional observational study was conducted on 175 adult patients with stage 3-5 chronic kidney disease (CKD) by using 51 healthy age-sex-matched Vietnamese adults as the control group. We next examined the prevalence of anemia and determined the serum iron and ferritin concentrations and TIBC. Anemia in CKD was defined as hemoglobin levels
zot C Abstract The French-speaking Society of Nephrology, Dialysis and Transplantation conducted, in 2018, a survey among French nephrologists into their iron prescribing habits for patients with chronic kidney disease stages 3 to 5 before dialysis. The results show that 73% of nephrologists use intravenous iron before dialysis stage. When a patient has gastrointestinal symptoms under oral iron therapy, only 48% of nephrologists use intravenous route. The starting thresholds for iron are for 78% of nephrologists a transferrin saturation
Vadadustat achieved primary efficacy and cardiovascular safety endpoints Clear, consistent top-line data advances plan for vadadustat's New Drug Application and other global regulatory submissions Company to discuss top-line data on its scheduled fir... Biopharmaceuticals Akebia Therapeutics, vadadustat, chronic kidney disease
Chronic kidney disease (CKD) is highly prevalent within South Africa.1 End-stage renal disease requires renal replacement therapies such as dialysis or transplant. However, due to limited resources in the public sector, very few patients are accepted into renal replacement programs.2 Goals of dietary management aim to treat many of the nutritional complications of the disease including metabolic bone disease, anemia, metabolic acidosis, and malnutrition.3 It is therefore imperative that measures are sought to delay the progression of the disease as well as minimize and manage symptoms for patients on dialysis.
Conclusion: For the treatment of anemia in Chinese patients with CKD ND, roxadustat is much more effective than a placebo; moreover, it is cost-effective at conventional WTP thresholds. PMID: 32249625 [PubMed - as supplied by publisher]
Semin Thromb Hemost DOI: 10.1055/s-0040-1708841Rates of thrombosis and bleeding episodes are both increased in patients with advanced chronic kidney disease (CKD). The pathogenic mechanisms of thrombosis in these patients include platelet activation, increased formation of platelet-leukocyte conjugates, and platelet-derived microparticles, as well as effects of uremic toxins on platelets. On the other side of the coin, platelet hyporeactivity mediated by uremic toxins and anemia contributes to the increased bleeding risk in advanced CKD. Platelets also contribute to the inflammatory environment, thus increasing the risk of...
Purpose of review We will examine the current and future options in management of anemia in dialysis patients focusing on recent trials in iron supplementation and alternatives to erythropoietin-stimulating agents (ESAs). Recent findings We review the literature on Erythropoietin (EPO)-stimulating agents, focusing on the risk benefits of various options available. We review the recent practice changing trial in iron supplementation in dialysis patients with chronic kidney disease and movements in the research on alternatives to EPO-stimulating agents primarily hypoxia-inducible factor prolyl hydroxylase inhibitors (HI...
Publication date: May 2020Source: Pharmacological Research, Volume 155Author(s): Junduo Liu, Afang Zhang, John C. Hayden, Akshaya Srikanth Bhagavathula, Fatema Alshehhi, Giulia Rinaldi, Vasileios Kontogiannis, Jamal Rahmani
AbstractBackgroundResponsiveness to erythropoietin-stimulating agents (ESAs) is important for anemia management in chronic kidney disease (CKD). We assessed the effects of a continuous erythropoietin receptor activator (CERA) on renoprotection beyond anemia management and the correlation between the responsiveness to ESAs and oxidative stress markers in CKD.MethodsThis single-center, prospective, observational study was conducted over 24 months. We administered CERA to 35 non-dialysis patients with hemoglobin (Hb)
CONCLUSIONS: Our study suggests that CAC progression in dialysis is a complex phenomenon, associated with several risk factors with special regard to elevated basal scores. This progression can be avoided or slowed with appropriate management, which must begin in the early stages of chronic kidney disease. PMID: 32127198 [PubMed - as supplied by publisher]
Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial ® iron, a new generation oral iron with high absorption and bioavailability and a...